RxDoctor Payments Data

David Meyer, MD

Neurology · Winston-Salem, NCNPI 1205879558

Payments from drug & device makers

$154,799in general payments, 2019–2025

Across 305 payments — averaging $507.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$83K
  • AstraZeneca$49K
  • Sanofi$8K
  • AbbVie$7K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Bristol Myers Squibb$1K
  • plus $3K from 12 others

What the payments were for

  • Consulting fees$39,99226%
  • Speaking & faculty fees$89,60758%
  • Travel & lodging$16,49311%
  • Food & beverage$8,5446%
  • Education$1630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$154,799 in reported general payments places this provider in the 85th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$136,027
Medicare patients
163
Services billed
13,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide69$700,849
CopaxoneGlatiramer Acetate49$377,657
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5027$290,379
Rebif RebidoseInterferon Beta-1a/Albumin26$285,075
TecfideraDimethyl Fumarate17$220,094
TysabriNatalizumab20$179,604
Avonex Pen (4 Pack)Interferon Beta-1a20$164,257
RebifInterferon Beta-1a/Albumin14$148,022
BetaseronInterferon Beta-1b15$137,070
Teriflunomide130$122,444
UbrelvyUbrogepant50$80,665
NuplazidPimavanserin Tartrate12$59,140
GlatopaGlatiramer Acetate21$53,479
BotoxOnabotulinumtoxina39$47,889
Emgality PenGalcanezumab-Gnlm48$37,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$8,482$700,84969 claims
BiogenTecfidera, Tysabri$452$399,69737 claims
Teva Pharmaceuticals USA, Inc.Copaxone$837$377,65749 claims
EMD Serono, Inc.Rebif$83,451$148,02214 claims
AbbVieUbrelvy, Botox, Qulipta$6,841$144,156102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 566 neurology providers in North Carolina.

Other neurology in Winston-Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →